Survodutide Research: Clinical Studies, Evidence & Scientific Review (2026)

From Peptidepedia, the trusted peptide wiki.

Research Evidence

Phase 2 Obesity Trial (Lancet Diabetes & Endocrinology, 2023)

A randomized, double-blind, placebo-controlled dose-finding trial in adults with BMI ≥27 without type 2 diabetes tested four doses of survodutide (0.6, 2.4, 3.6, and 4.8 mg) over 46 weeks (20 weeks dose escalation + 26 weeks maintenance):

0.6 mg: 6.2% weight loss
2.4 mg: 12.5% weight loss
3.6 mg: 13.2% weight loss
4.8 mg: 14.9% weight loss (vs 2.8% placebo)
4.8 mg treatment completers: 18.7% weight loss

At the highest dose, 83% of participants lost ≥5% body weight, 69% lost ≥10%, and 55% lost ≥15%.

Phase 2b MASH Trial (New England Journal of Medicine, 2024)

The landmark MASH trial enrolled patients with biopsy-confirmed MASH and fibrosis stages F1-F3. After 48 weeks of treatment, results on the primary endpoint of MASH improvement without fibrosis worsening were:

2.4 mg: 47% (vs 14% placebo)
4.8 mg: 62% (vs 14% placebo)
6.0 mg: 43% (vs 14% placebo)

The 62% MASH resolution rate at the 4.8 mg dose is the highest reported in any randomized controlled MASH trial. Liver fat reduction of ≥30% was achieved in 67% of participants at 4.8 mg (vs 14% placebo). Fibrosis improvement of ≥1 stage occurred in 36% at 4.8 mg (vs 22% placebo), rising to 64.5% in the F2/F3 subgroup at 6 mg.

Head-to-Head vs Semaglutide

In a Phase 2 trial comparing survodutide to open-label semaglutide 1.0 mg in patients with type 2 diabetes (published in Diabetologia, 2024), survodutide ≥1.8 mg produced 8.7% weight loss versus 5.3% for semaglutide at 16 weeks, with comparable or superior HbA1c reductions at higher doses.

Phase 3 Program (SYNCHRONIZE)

Boehringer Ingelheim's Phase 3 program includes multiple large-scale trials:

SYNCHRONIZE-1 (NCT06066515): 726 participants with obesity, no T2DM. Testing 3.6 mg and 6 mg vs placebo over 76 weeks. Topline data expected H1 2026.
SYNCHRONIZE-2 (NCT06066528): Obesity with T2DM. Same doses, 76 weeks. Topline expected H1 2026.
SYNCHRONIZE-CVOT (NCT06077864): 5,508 participants with obesity and established CV disease or CKD. Primary endpoint: 5-point MACE. Conducted across 34 countries and 524 sites.
LIVERAGE (NCT06632444): ~1,800 participants with MASH and F2/F3 fibrosis. 52-week efficacy endpoint with ~7 year long-term follow-up.

Phase 3 trials use 4-week dose escalation intervals (vs 2-week in Phase 2) to reduce gastrointestinal side effects.

Frequently Asked Questions

Survodutide (GLP-1 + glucagon), tirzepatide (GLP-1 + GIP), and retatrutide (GLP-1 + GIP + glucagon) represent three different multi-receptor approaches. Cross-trial comparisons suggest retatrutide may produce the highest weight loss (~24%), followed by tirzepatide (~21%), survodutide (~18.7%), and semaglutide (~15%). Direct comparison is limited since no Phase 3 head-to-head data exists.

No. Survodutide is an investigational drug that has not been approved by any regulatory agency. It received FDA Breakthrough Therapy Designation for MASH in September 2024 and is currently in Phase 3 trials for both obesity and MASH.

Gastrointestinal side effects are the most common: nausea (66%), diarrhea (49%), and vomiting (41%) in Phase 2 trials. Discontinuation rates due to side effects were 20-25%, primarily during the dose-escalation phase. Phase 3 trials use slower dose titration (4-week intervals) to mitigate this.

In the Phase 2b MASH trial published in the New England Journal of Medicine, survodutide achieved 62% MASH resolution without fibrosis worsening (vs 14% placebo) — the highest rate reported in any MASH trial. The glucagon receptor directly reduces liver fat through enhanced hepatic lipid oxidation, an effect GLP-1-only drugs cannot replicate.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.